2015
Press/Media Releases:
Additional Phase 3 Data Supporting OPKO's Rayaldee™ as a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at Kidney Week 2015
November 5, 2015
FDA Accepts OPKO's New Drug Application for Rayaldee™
July 28, 2015
OPKO Announces Submission of Rayaldee™ New Drug Application to U.S. Food and Drug Administration
May 29, 2015
Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings
March 27, 2015
Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference
March 6, 2015 |
